Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma
ConclusionsAs seen in previously reported cases, erlotinib is a therapeutic option in advanced chordoma, even in imatinib refractory cases and thus warrants exploration of its therapeutic role in prospective clinical trials.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chordoma | Clinical Trials | Gleevec | Palliative | Sarcomas | Tarceva